Incorporating patient reporting patterns to evaluate spatially targeted TB interventions.
Tuberculosis heterogeneity
Tuberculosis in Dhaka
Tuberculosis patient-level reporting
Journal
Annals of epidemiology
ISSN: 1873-2585
Titre abrégé: Ann Epidemiol
Pays: United States
ID NLM: 9100013
Informations de publication
Date de publication:
02 2021
02 2021
Historique:
received:
19
08
2020
revised:
26
10
2020
accepted:
02
11
2020
pubmed:
10
11
2020
medline:
2
3
2021
entrez:
9
11
2020
Statut:
ppublish
Résumé
Tuberculosis (TB) is geographically heterogeneous, and geographic targeting can improve the impact of TB interventions. However, standard TB notification data may not sufficiently capture this heterogeneity. Better understanding of patient reporting patterns (discrepancies between residence and place of presentation) may improve our ability to use notifications to appropriately target interventions. Using demographic data and TB reports from Dhaka North City Corporation and Dhaka South City Corporation, we identified wards of high TB incidence and developed a TB transmission model. We calibrated the model to patient-level data from selected wards under four different reporting pattern assumptions and estimated the relative impact of targeted versus untargeted active case finding. The impact of geographically targeted interventions varied substantially depending on reporting pattern assumptions. The relative reduction in TB incidence, comparing targeted with untargeted active case finding in Dhaka North City Corporation, was 1.20, assuming weak correlation between reporting and residence, versus 2.45, assuming perfect correlation. Similar patterns were observed in Dhaka South City Corporation (1.03 vs. 2.08). Movement of individuals seeking TB diagnoses may substantially affect ward-level TB transmission. Better understanding of patient reporting patterns can improve estimates of the impact of targeted interventions in reducing TB incidence. Incorporating high-quality patient-level data is critical to optimizing TB interventions.
Identifiants
pubmed: 33166716
pii: S1047-2797(20)30410-5
doi: 10.1016/j.annepidem.2020.11.003
pmc: PMC9612399
mid: NIHMS1841514
pii:
doi:
Types de publication
Journal Article
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
7-10Subventions
Organisme : NIMH NIH HHS
ID : F32 MH128120
Pays : United States
Organisme : NIAID NIH HHS
ID : T32 AI052074
Pays : United States
Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.
Références
Lancet Infect Dis. 2018 Jul;18(7):788-795
pubmed: 29681517
Lancet Infect Dis. 2019 Mar;19(3):e89-e95
pubmed: 30554997
Epidemiol Infect. 2021 Apr 19;149:e106
pubmed: 33866998
BMC Infect Dis. 2018 Jul 4;18(1):299
pubmed: 29973140
Int J Tuberc Lung Dis. 2019 Apr 1;23(4):433-440
pubmed: 31064622
Epidemiol Infect. 2021 Sep 02;149:e209
pubmed: 35506926
Lancet. 2015 Dec 5;386(10010):2334-43
pubmed: 26515675
Proc Natl Acad Sci U S A. 2012 Jun 12;109(24):9557-62
pubmed: 22645356
PLoS One. 2013 Oct 16;8(10):e77517
pubmed: 24147015
J R Soc Interface. 2016 Mar;13(116):
pubmed: 27009179